Creo's Speedboat Inject to be evaluated by NICE

Surgical endoscopy specialist Creo Medical Group announced on Thursday that its ‘Speedboat Inject’ product had been chosen by the National Institute for Health and Care Excellence (NICE) for further evaluation and guidance in the endoscopic submucosal dissection (ESD) of lower gastrointestinal (GI) lesions.

The AIM-traded firm said NICE's decision to select Speedboat Inject for scoping and routing came after a thorough committee review of the product's headline data.

It said it initiated a multi-step process in which Speedboat's clinical and economic evidence for lower GI ESD, along with other relevant data, would be evaluated by NICE.

If deemed appropriate, the evaluation could result in specific NICE output, such as medical technologies guidance.

“We are delighted that Speedboat Inject has reached this stage with NICE and the validation this provides given the progress we are already making in the UK,” said chief executive officer Craig Gulliford.

“We look forward to the outcome of the final stages of the review process as NICE concludes its work.”

At 1501 BST, shares in Creo Medical Group were down 0.85% at 24.39p.

Reporting by Josh White for Sharecast.com.